AVAC
Global Advocacy for HIV Prevention

The Future of ARV-Based Prevention and More *(October 2022)*

The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women. (Visit *www.avac.org/hvad* for vaccine and broadly neutralizing antibody pipelines.)

PRE-CLINICAL

- TAF — **CONRAD**
- CAB — **CONRAD**
- CAB — **CONRAD**
- TNFV — **Gilead**
- F/TAF — **Houston Methodist**
- 5P12 — **Mintaka**
- MAVR, TNFV — **Nigerian Institute for Medical Research**
- CAB — **PATH/ Queens University Belfast**
- DS03 — **Queen's University Belfast**
- BNAB — **Rockefeller University**
- TAF — **RTI**
- DPVR — **University of Pittsburgh**
- CAB — **ViiV**
- MAVR — **ViiV/Pfizer**

PHASE I

- ELVG, TAF — **CONRAD**
- TNFV — **Johns Hopkins**
- ISL — **Merck**[3]
- TAF — **Oak Crest /CAPRISA**
- OB2H — **Orion**
- DS03 — **Pop Council**
- DPVR — **Pop Council**[1] *3-monthly*
- MK20 — **University of Pittsburgh**
- GRFS — **University of Pittsburgh**

PHASE II

PHASE III/IIIb/IV

- F/TAF — **Gilead** *Daily*
- LEN — **Gilead** *6-monthly*
- CAB — **ViiV-GSK**[2] *2-monthly*
- ISL — **Merck**[3] *1-monthly*
- DPVR — **Pop Council** *1-monthly*

Multipurpose Prevention Technologies (MPTs)

- ETED, ACZX, TNFV — **Auritec**
- ACZX, TNFV — **CONRAD**
- CAB, LVGR — **CONRAD**
- TNFV, EFAV — **i3S/University of Porto**
- PRGT, ISL — **Magee-Women's Research Institute /University of Pittsburg**
- F/TDF, MAB — **Oak Crest /University of North Carolina**
- PC05 — **PATH /Pop Council /Kessel**
- CAB, PRGT — **PATH/Queens University Belfast**
- ETGS, GRFS, ETED — **Pop Council**
- CRGN, GRFS — **Pop Council /Evofem Biosciences**
- **RTI**[5]
- F/TDF, MAB — **UMass and Planet Biotechnology /Oak Crest /MassBiologics**
- DPVR, PRTV, LVGR — **University of North Carolina**
- ETGS, ISL, ETED — **University of North Carolina**
- DPVR, LVGR, PRTV — **University of North Carolina**
- ISL — **University of North Carolina**
- PPCM — **Yaso Therapeutics**
- TAF, ELVG — **CONRAD**
- DPVR, LVGR — **Pop Council**
- DPVR, LVGR — **Pop Council**
- TNFV — **CONRAD**
- TNFV, LVGR — **CONRAD**
- F/TAF, ETED, LVGR — **Pop Council /Medicines360**[4]
- F/TDF, ETED, LVGR — **Viatris**[4]

[1] This is a Bioequivalency trial with the monthly DVR.

[2] Dec. 2021 Approved by the FDA; Aug. 2022 Approved by the Australian regulatory agency

[3] Discontinued in Sept. 2022

[4] These two dual pill products are undergoing bioequivalency trials. The drug components are approved, but not in their combination. Therefore, it does not follow the traditional R&D pathway.

[5] Non-specific to any drug; for development of a long-acting biodegradable implant suitable for an MPT use to protect against pregnancy and HIV. See SCHIELD Implant for more information.

DELIVERY SYSTEM

- **Diaphragm**
- **Enema**
- **Intramuscular injection**
- **Implant**
- **Micro-array patch**
- **Non-specific mucosal insert**
- **Oral pills**
- **Subcutaneous injection**
- **Vaginal film**
- **Vaginal gel**
- **Vaginal insert**
- **Vaginal ring**

ACTIVE DRUG

5P12	5P12-RANTES
ACZX	Acyclovir-Zovirax
AMPR	Amphora
BNAB	Broadly neutralizing antibody
CAB	Cabotegravir/ GSK 744
CRGN	Carrageenan
DPVR	Dapivirine
F/TAF	Descovy
DLGR	Dolutegravir
DS03	DS003 (BMS793)
EFAV	Efavirenz
ELVG	Elvitegravir
ETED	Ethinylestradiol
ETGS	Etonogestrel
GRFS	Griffithsin
ISL	Islatravir
LEN	Lenacapavir
LVGR	Levonorgestrel
MAVR	Maraviroc
MK20	MK-2048
MAB	Monoclonal antibody
OB2H	OB-002H
PC05	PC-1005
PPCM	PPCM polyanionic microbicide
PRTV	Pritelivir
PRGT	Progestin
TNFV	Tenofovir
TAF	Tenofovir Alafenamide
F/TDF	Truvada